Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) have earned a consensus rating of “Hold” from the twelve research firms that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $8.8750.

Several equities analysts recently weighed in on IOVA shares. Citizens Jmp raised Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 price objective for the company in a research report on Tuesday, March 3rd. Barclays raised their target price on Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $2.00 price target on shares of Iovance Biotherapeutics in a research report on Thursday, February 5th. Wall Street Zen raised Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Chardan Capital lowered their price objective on shares of Iovance Biotherapeutics from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th.

Institutional Trading of Iovance Biotherapeutics

Hedge funds have recently bought and sold shares of the stock. Vontobel Holding Ltd. acquired a new stake in Iovance Biotherapeutics in the 3rd quarter worth $26,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Iovance Biotherapeutics during the third quarter valued at about $27,000. Arcataur Capital Management LLC bought a new stake in shares of Iovance Biotherapeutics in the fourth quarter valued at about $29,000. Granite Investment Partners LLC bought a new stake in shares of Iovance Biotherapeutics in the fourth quarter valued at about $29,000. Finally, Motley Fool Asset Management LLC acquired a new stake in Iovance Biotherapeutics during the fourth quarter worth about $29,000. 77.03% of the stock is owned by institutional investors.

Iovance Biotherapeutics Price Performance

Shares of IOVA opened at $3.51 on Friday. The company has a market capitalization of $1.45 billion, a PE ratio of -3.13 and a beta of 0.69. Iovance Biotherapeutics has a one year low of $1.64 and a one year high of $5.63. The company’s fifty day moving average price is $3.32 and its 200 day moving average price is $2.67.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. The company had revenue of $86.77 million during the quarter, compared to analysts’ expectations of $81.61 million. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.54%. Analysts anticipate that Iovance Biotherapeutics will post -1.24 earnings per share for the current year.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.